ESLICARBAZEPINE ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE).
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
| Metabolism | Eslicarbazepine acetate is rapidly hydrolyzed by esterases in the liver and blood to the active metabolite eslicarbazepine. Eslicarbazepine is further metabolized via glucuronidation (UGT1A4, UGT1A9, UGT2B7) and, to a minor extent, by CYP3A4 oxidation. |
| Excretion | Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible. |
| Half-life | Terminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing. |
| Protein binding | Eslicarbazepine acetate: ~40% bound to plasma proteins (primarily albumin); eslicarbazepine: ~30% bound. |
| Volume of Distribution | Eslicarbazepine: Vd/F ~2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: At least 80% (absolute bioavailability due to extensive first-pass metabolism; eslicarbazepine acetate is a prodrug rapidly converted to eslicarbazepine). |
| Onset of Action | Oral: Time to peak plasma concentration (Tmax) is 1-4 hours; clinical effect (seizure reduction) typically observed within 1-2 weeks of starting therapy. |
| Duration of Action | Oral: Duration of antiepileptic effect corresponds to dosing interval (24 hours with once-daily dosing); steady-state achieved within 4-5 days. |
| Molecular Weight | 337.38 |
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
| Dosage form | TABLET |
| Renal impairment | CrCl >30 mL/min: no adjustment. CrCl 15-30 mL/min: reduce dose by 50% (max 600 mg/day). CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (max 600 mg/day). Child-Pugh C: not recommended. |
| Pediatric use | Not established; off-label doses range from 20-40 mg/kg/day divided twice daily, but no FDA approved pediatric dosing. |
| Geriatric use | Start at 200 mg daily; consider lower titration due to decreased renal function; monitor for hyponatremia and dizziness. |
| 1st trimester | Avoid unless benefit outweighs risk. Associated with increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) based on animal studies and limited human data. |
| 2nd trimester | Use only if clearly needed; may cause fetal adverse effects. Monitor for reduced efficacy due to pregnancy-induced pharmacokinetic changes. |
| 3rd trimester | Avoid in late pregnancy due to risk of neonatal hemorrhage (vitamin K-dependent coagulation factor deficiency) and withdrawal symptoms. Taper if possible before delivery. |
Clinical note
Comprehensive clinical and safety monograph for ESLICARBAZEPINE ACETATE (ESLICARBAZEPINE ACETATE).
| Placental transfer | Eslicarbazepine acetate crosses the placenta. Fetal plasma concentrations approximately 50-60% of maternal levels based on data from active metabolite eslicarbazepine. |
| Breastfeeding | Eslicarbazepine acetate and its metabolite are excreted into human breast milk in low concentrations. Monitor infant for sedation, poor feeding, and withdrawal symptoms. Consider risk-benefit. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to eslicarbazepine acetate or any excipientSecond- or third-degree atrioventricular block
| Precautions | Hyponatremia (sodium <125 mmol/L), particularly in elderly or patients on diuretics; suicidal thoughts and behavior; dizziness and somnolence; ataxia and gait disturbance; multiorgan hypersensitivity reactions; hematologic abnormalities (leukopenia, thrombocytopenia); liver enzyme elevations; withdrawal seizures upon abrupt discontinuation; teratogenicity (pregnancy category C); drug interactions (especially with carbamazepine, phenytoin, and oral contraceptives). |
| Food/Dietary | No significant food interactions. Alcohol may increase CNS depression; advise avoidance. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Eslicarbazepine acetate is associated with an increased risk of major congenital malformations, particularly neural tube defects, craniofacial defects, and cardiovascular malformations, when used during the first trimester. In the second and third trimesters, exposure may be associated with adverse neurodevelopmental outcomes and growth restriction. Data are derived from studies on eslicarbazepine and the related compound oxcarbazepine, as eslicarbazepine is the active metabolite. Risk is dose-dependent and higher with polytherapy. |
| Fetal Monitoring | Monitor maternal eslicarbazepine trough levels monthly during pregnancy and postpartum due to altered pharmacokinetics. Perform fetal ultrasound at 18-20 weeks gestation to screen for structural anomalies. Assess fetal growth by serial ultrasound in third trimester. Monitor maternal for signs of toxicity (e.g., dizziness, ataxia, diplopia) and adjust dose as needed. Postnatally, monitor infant for withdrawal symptoms (e.g., irritability, feeding difficulties, jitteriness) and ensure blood clotting studies (vitamin K-dependent) are normal. |
| Fertility Effects | Eslicarbazepine acetate may reduce efficacy of hormonal contraceptives due to enzyme induction (CYP3A4), potentially affecting fertility planning. There is no direct evidence of impairment of fertility in humans; animal studies show no significant effects on male or female fertility at clinically relevant doses. However, polytherapy with enzyme-inducing antiepileptics may exacerbate effects on hormonal contraceptives. |
| Clinical Pearls | Titrate slowly to minimize CNS adverse effects; target maintenance doses are typically 400-1200 mg once daily. Avoid abrupt discontinuation due to risk of increased seizure frequency. Monitor serum sodium levels, especially in elderly or patients on concomitant hyponatremic drugs, due to risk of hyponatremia. Does not require dose adjustment in mild-to-moderate renal impairment. May cause dizziness and somnolence; caution with activities requiring alertness. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with or without food. · Swallow the tablet whole; do not crush or chew. · Do not stop taking this medication suddenly, as this may increase seizure frequency. · Avoid driving or operating heavy machinery until you know how this drug affects you, as it may cause dizziness or drowsiness. · Contact your doctor if you experience symptoms of low sodium (e.g., headache, confusion, nausea). · Inform all healthcare providers that you take this medication, especially before lab tests or surgery. · Store at room temperature, away from moisture and heat. |